JUVISE PHARMACEUTICAL: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
JUVISE PHARMACEUTICAL
Largest movements
- Cash -€170
down €170 (-23.2%), from €734 to €564
mainly Net result for the year (-€1,303)
- Profit (loss) carried forward -€1,303
down €1,303 (-0.6%), from -€232,575 to -€233,878
- Trade debts +€1,133
up €1,133 (+948%), from €119 to €1,252
- Gross operating margin +€994
up €994 (+44.2%), from -€2,246 to -€1,252
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €734 | €564 | -€170 | -23.2% |
| Current assets | 29/58 | €734 | €564 | -€170 | -23.2% |
| Cash at bank and in hand | 54/58 | €734 | €564 | -€170 | -23.2% |
| Total equity and liabilities | 10/49 | €734 | €564 | -€170 | -23.2% |
| Equity | 10/15 | -€226,375 | -€227,678 | -€1,303 | -0.6% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€232,575 | -€233,878 | -€1,303 | -0.6% |
| Amounts payable | 17/49 | €227,108 | €228,241 | +€1,133 | +0.5% |
| Amounts payable within one year | 42/48 | €227,108 | €228,241 | +€1,133 | +0.5% |
| Trade debts | 44 | €119 | €1,252 | +€1,133 | +948% |
| Suppliers | 440/4 | €119 | €1,252 | +€1,133 | +948% |
| Other amounts payable | 47/48 | €226,989 | €226,989 | = | 0.0% |
| Gross operating margin | 9900 | -€2,246 | -€1,252 | +€994 | +44.2% |
| Operating profit (loss) | 9901 | -€2,246 | -€1,252 | +€994 | +44.2% |
| Financial charges | 65/66B | €42 | €51 | +€9 | +20.5% |
| Recurring financial charges | 65 | €42 | €51 | +€9 | +20.5% |
| Profit (loss) for the period before taxes | 9903 | -€2,288 | -€1,303 | +€985 | +43.1% |
| Profit (loss) for the period | 9904 | -€2,288 | -€1,303 | +€985 | +43.1% |
| Profit (loss) for the period to be appropriated | 9905 | -€2,288 | -€1,303 | +€985 | +43.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 21 October 2026 via checked.be.